Towards a science of community stakeholder engagement in biomedical HIV prevention trials: An embedded four-country case study

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Newman, Peter A ^a   Rubincam, Clara ^a   Slack, Catherine ^b   Essack, Zaynab ^b   Chakrapani, Venkatesan ^c   Chuang, Deng Min ^a   Tepjan, Suchon ^a   Shunmugam, Murali ^c   Roungprakhon, Surachet ^d   Logie, Carmen ^a   Koen, Jennifer ^b   Lindegger, Graham ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Centre for Sexuality and Health Research and Policy (C SHaRP)   (India)

^d RAJAMANGALA UNIVERSITY OF TECHNOLOGY PHRA NAKHON   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANADA; CASE STUDY; FEMALE; FUNDING; HEALTH CARE DISPARITY; HEALTH LITERACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INFECTION PREVENTION; INVESTMENT; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PRACTICE GUIDELINE; RISK ASSESSMENT; SOUTH AFRICA; THAILAND; TREND STUDY; ATTITUDE TO HEALTH; CLINICAL TRIAL (TOPIC); COMMUNITY PARTICIPATION; HIV INFECTIONS; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; NOMENCLATURE; ORGANIZATION AND MANAGEMENT;

ADULT; BIOMEDICAL RESEARCH; CANADA; CLINICAL TRIALS AS TOPIC; COMMUNITY PARTICIPATION; FEMALE; FOCUS GROUPS; GUIDELINES AS TOPIC; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; INDIA; INTERNATIONAL COOPERATION; MALE; SOUTH AFRICA; TERMINOLOGY AS TOPIC; THAILAND;

EID: 84942911449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135937     Document Type: Article

References (68)

1. UNAIDS-AVAC. Good participatory practice: guidelines for biomedical HIV prevention trials. UNAIDS. Published June, 2011 [cited 2015 Feb 11]. Available from: http://www.unaids.org/sites/default/files/media-asset/JC1853-GPP-Guidelines-2011-en-0.pdf.
2. Singh J, Mills E. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med. 2005; 2(9):e234. PMID: 16008507
3. Ukpong M, Peterson K. Oral tenofovir controversy II: voices from the field, a series of reports of the oral tenofovir trials from the perspectives of active stakeholder voices engaged on the field in Cambodia, Cameroon, Nigeria, Thailand and Malawi. New HIV Vaccine and Microbicide Advocacy Society (NHVMAS). Published 2009 [cited 2015 Feb 11]. Available from: http://www.nhvmas-ng.org/publication/TDF2.pdf.
4. McGrory E, Irvin A, Heise L. Research Rashomon: lessons from the Cameroon pre-exposure prophylaxis trial site. Global campaign for microbicides. Published 2009 [cited 2015 Feb 11]. Available from: www.global-campaign.org/clientfiles/Cameroon.pdf.
5. UNAIDS-AVAC. Good participatory practice: guidelines for biomedical HIV prevention trials. UNAIDS. Published November, 2007 [cited 2015 Feb 11]. Available from: http://whqlibdoc.who.int/unaids/2007/9789291736348-eng.pdf.
6. UNAIDS-WHO. Ethical considerations in biomedical HIV prevention trials: UNAIDS-WHO guidance document. UNAIDS. Published July, 2007 [cited 2015 Feb 11]. Available from: http://www.aidsdatahub.org/sites/default/files/documents/UNAIDS-WHO-Guidance-DocumentEthical-Considerations-in-Biomedical-HIV-Prevention-Trials-2007.pdf.
7. AVAC. GPP blueprint for stakeholder engagement. AVAC. Published February, 2014 [cited 2015 Jun 15]. Available from: http://www.avac.org/resource/gpp-blueprint-stakeholder-engagement.
8. Tindana P, Singh J, Tracy C, Upshur RE, Daar AS, Singer PA, et al. Grand challenges in global health: community engagement in research in developing countries. PLoS Med. 2007; 4(9):e273. PMID: 17850178
9. Nakibinge S, Maher D, Katende J, Kamali A, Grosskurth H, Seeley J. Community engagement in health research: two decades of experience from a research project on HIV in rural Uganda. Trop Med Int Health. 2009; 14(2):190-195. doi: 10.1111/j.1365-3156.2008.02207.x PMID: 19207175
10. Participants in the community engagement and consent workshop, Kilifi, Kenya, March 2011. Consent and community engagement in diverse research contexts: reviewing and developing research and practice. J Empir Res Hum Res Ethics. 2013; 8(4):1-18. doi: 10.1525/jer.2013.8.4.1 PMID: 24169417
11. Marsh V, Kamuya D, Rowa Y, Gikonyo C, Molyneux S. Beginning community engagement at a busy biomedical research programme: experiences from the KEMRI CGMRC-Wellcome Trust Research Programme, Kilifi, Kenya. Soc Sci Med. 2008; 67(5):721-33. doi: 10.1016/j.socscimed.2008.02.007 PMID: 18375028
12. Lavery JV, Tinadana PO, Scott TW, Harrington LC, Ramsey JM, Ytuarte-Nunez C, et al. Towards a framework for community engagement in global health research. Trends in Parasitol. 2010; 26(6):279-283.
13. Newman PA, Rubincam C. Advancing community stakeholder engagement in biomedical HIV prevention trials: principles, practices and evidence. Expert Rev Vaccines. 2014; 13(12): 1553-1562. doi: 10.1586/14760584.2014.953484 PMID: 25174764
14. Godfrey C, Schouten JT, Swindells S. Implementation of HIV-related clinical research in the international setting. J Acquir Immune Defic Syndr. 2014; 65(Suppl 1):S1-S2. doi: 10.1097/QAI.0000000000000032 PMID: 24321976
15. Newman PA. Towards a science of community engagement. Lancet. 2006; 367(9507):302. PMID: 16443036
16. Newman PA. Integrating social and biomedical science in HIV vaccine research: obstacles, opportunities and ways forward. Expert Rev Vaccines. 2012; 11(1):1-3. doi: 10.1586/erv.11.162 PMID: 22149699
17. Yin RK. Applications of case study research. 3rd ed. Thousand Oaks: Sage Publications; 2012.
18. Harriott RE, Firestone WA. Multisite qualitative policy research: optimizing description and generalizability. Educ Res. 1983; 12(2):14-19.
19. Merriam SB. Qualitative research and case study applications in education. San Francisco: Jossey-Bass Publishers; 1998.
20. Yin RK. Case study research: design and methods. 5th eds. Thousand Oaks: Sage Publications; 2014.
21. Mays N, Pope C. Qualitative research in health care: assessing quality in qualitative research. Educ Debate. 2000; 320:50-52.
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med 2009; 361(23):2209-2220.
23. Namwat C, Morgan PA, Premsiri N, Debyasuvern T, Pitisuttithum P, Bussaratid V, et al. Social impact of participation in a phase III HIV vaccine trial in Thailand. Poster presented at: AIDS Vaccine; 2007 Aug 20-23; Seattle, WA.
24. Newman PA, Chakrapani V, Weaver J, Shunmugam M, Rubincam C. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India. Vaccine. 2014; 32 (44):5854-5861. doi: 10.1016/j.vaccine.2014.08.043 PMID: 25173475
25. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept pase 2b study. Lancet Infect Dis. 2011; 11(7):507-515. doi: 10.1016/S1473-3099(11)70098-6 PMID: 21570355
26. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954
27. Duerr A, Huang Y, Buchbinder S, Coombs RS, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012; 206(2):258-266. doi: 10.1093/infdis/jis342 PMID: 22561365
28. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008; 359:463-473. doi: 10.1056/NEJMoa0707957 PMID: 18669425
29. Horwood J. Cellulose sulphate microbicide trial halted. Lancet Infect Dis. 2007; 7(3)183.
30. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-1174. doi: 10.1126/science.1193748 PMID: 20643915
31. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised, controlled trial. Lancet. 2002; 360:962-964. PMID: 12383665
32. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-2599. doi: 10.1056/NEJMoa1011205 PMID: 21091279
33. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-2090. doi: 10.1016/S0140-6736(13)61127-7 PMID: 23769234
34. Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials. AIDS. 2003; 17(2):147-156. PMID: 12545073
35. Fonsart J, Capitant C, Spire B, Cotte L, Pialoux G, Lorente N, et al. High adherence rate to intermittent oral PrEP with TDF/FTC among high risk MSM (ANRS IPERGAY) [abstract]. 20th International AIDS Conference; 2014 Jul 20-25; Melbourne, Australia; TUAC0103.
36. National AIDS Control Organisation. HIV sentinel surveillance 2012-13: a technical brief. NACO. Published 2012 [cited 2015 Jun 15]. Available from: http://www.naco.gov.in/upload/NACP%20-%20IV/HSS%20TECHNICAL%20BRIEF/HIV%20Sentinel%20Surveillance%20Technical%20Brief.pdf.
37. Chakrapani V, Newman PA, Singhal N, Nelson R, Shunmugam M. "If it's not working, why would they be testing it?": mental models of HIV vaccine trials and preventive misconception among men who have sex with men in India. BMC Pub Health. 2013; 13:731.
38. UNAIDS. Thailand: HIV and AIDS estimates (2013). Published 2013 [cited 2015 Jun 15]. Available from: http://www.unaids.org/en/regionscountries/countries/thailand.
39. Allen M, Lau C-Y. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention. Soc Sci Med. 2008; 66(4):945-951. PMID: 18162272
40. Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008; 26(8):1091-1097. doi: 10.1016/j.vaccine.2007.12.016 PMID: 18237829
41. Koblin BA, Holte S, Lenderking B, Heagerty P. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET vaccine preparedness study protocol team. J Acquir Immune Defic Syndr. 2000; 24(5):451-457. PMID: 11035616
42. Kegeles SM, Johnson MO, Strauss RP, Ralston B, Hays RB, Metzger DS, et al. How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out. AIDS Educ Prev. 2006; 18 (6):560-572. PMID: 17166081
43. Burnard P, Gill P, Steward K, Treasure E, Chadwick B. Analysing and presenting qualitative data. Br Dent J. 2008; 204:249-432.
44. Charmaz KC. Constructing grounded theory: a practical guide through qualitative analysis. Thousand Oaks: Sage Publications; 2006.
45. Strauss AL, Corbin JM. Basics of qualitative research: techniques and procedures for developing grounded theory. 4th ed. Thousand Oaks, CA: Sage Publications; 1998.
46. Creswell JW, Miller DL. Determining validity in qualitative inquiry. Theory Pract. 2000; 39(3):124-130.
47. Essack Z, Koen J, Slack C, Lindegger G, Newman PA. Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials. AIDS Care. 2012; 24(10):1249-1254. doi: 10.1080/09540121.2012.656566 PMID: 22360605
48. Koen J, Essack Z, Slack C, Lindegger G, Newman PA. "It looks like you just want them when things get rough": civil society perspectives on negative trial results and stakeholder engagement in HIV prevention trials. Dev World Bioeth. 2013; 13(3):138-148. doi: 10.1111/j.1471-8847.2012.00338.x PMID: 22998395
49. Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR; NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA. 2010; 304(3):275-283. doi: 10.1001/jama.2010.926 PMID: 20639561
50. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007; 4(11)e324. PMID: 18044980
51. Lally M, Goldsworthy R, Sarr M, Kahn J, Brown L, Peralta L, et al. Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials. J Adolesc Health. 2014; 55(2):254-259. doi: 10.1016/j.jadohealth.2014.01.006 PMID: 24613097
52. Rautenbach C, Lindegger G, Slack C, Wallace M, Newman PA. I'm positive, but I'm negative: competing voices in informed consent and implications for HIV vaccine trials. J Empir Res Hum Res Ethics. 2015; 10(2),151-156. doi: 10.1177/1556264615575509 PMID: 25819758
53. Kagan JM, Rosas SR, Siskind RL, Campbell RD, Gondwe D, Munroe D, et al. Community-researcher partnership at NIAID HIV/AIDS clinical trials sites: insights for evaluation and enhancement. Prog Community Health Partnersh. 2012; 6(3):311-320. doi: 10.1353/cpr.2012.0034 PMID: 22982844
54. West Slevin K, Ukpong M, Heise L. Community engagement in HIV prevention trials: evolution of the field and opportunities for growth. Aids2031 Science and Technology Working Group. Published November, 2008 [cited 2015 Feb 12]. Available from: http://www.path.org/publications/files/aids2031-comm-engage.pdf.
55. Allman D, Ditmore MH, Kaplan K. Improving ethical and participatory practice for marginalized populations in biomedical HIV prevention trials: lessons from Thailand. PLoS One. 2014; 9(6):e100058. doi: 10.1371/journal.pone.0100058 PMID: 24949864
56. Mack N, Kirkendale S, Omullo P, Odhiambo J, Ratlhagana M, Masaki M, et al. Implementing good participatory practice guidelines in the FEM-PrEP preexposure prophylaxis trial for HIV prevention among African women: a focus on local stakeholder involvement. Open Access J Clin Trials. 2013; 5:127-135.
57. Kolopack PA., Parsons JA, Lavery JV. What makes community engagement effective?: lessons from the Eliminate Dengue Program in Queensland, Australia. PLoS Negl Trop Dis. 2015; 9(4):e0003713. doi: 10.1371/journal.pntd.0003713 PMID: 25875485
58. Delany-Moretlwe S, Stadler J, Mayaud P, Rees H. Investing in the future: lessons learnt from communicating the results of HSV/HIV intervention trials in South Africa. Health Res Policy Syst. 2011; 9(Suppl 1):S8. doi: 10.1186/1478-4505-9-S1-S8 PMID: 21679389
59. Mack N, Robinson ET, MacQueen KM, Moffett J, Johnson LM. The exploitation of "Exploitation" in the tenofovir prep trial in Cameroon: lessons learned from media coverage of an HIV prevention trial. J Empir Res Hum Res Ethics. 2010; 5(2):3-19. doi: 10.1525/jer.2010.5.2.3 PMID: 20569146
60. Newman PA, Logie C, James L, Charles T, Maxwell J, Salam K, et al. "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Public Health. 2011; 101(9):1749-1758. doi: 10.2105/AJPH.2011.300208 PMID: 21778490
61. Newman PA, Woodford M, Logie C. HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health. 2012; 7(1):87-100. doi: 10.1080/17441692.2010.549139 PMID: 21390966
62. MacQueen KM, Bhan A, Frolich J, Holzer J, Sugarman J, Ethics Working Group of the HIV Prevention Trials Network. Evaluating community engagement in global health research: the need for metrics. BMC Med Ethics. 2015; 16:44. doi: 10.1186/s12910-015-0033-9 PMID: 26126899
63. MacQueen KM, Harlan VS, West Slevin K, Hannah S, Bass E, Moffett J. 2012. Stakeholder engagement toolkit for HIV prevention trials. FHI 360. Published 2012 [cited 2015 Feb 12]. Available from: http://www.fhi360.org/resource/stakeholder-engagement-toolkit-hiv-prevention-trials.
64. Ragin DF, Ricci E, Rhodes R, Holohan J, Smirnoff M, Richardson LD. Defining the 'community' in community consultation for emergency research: findings from the community VOICES study. Soc Sci Med. 2008; 66(6):1379-1392. doi: 10.1016/j.socscimed.2007.10.022 PMID: 18237833
65. Jewkes R, Murcott A. Meanings of community. Soc Sci Med. 1996; 43(4):555-563. PMID: 8844956
66. Tindana P, de Vries J, Campbell M, Littler K, Seeley J, Marshall P, et al. Community engagement strategies for genomic studies in Africa: a review of the literature. BMC Med Ethics. 2015; 16(1):24.
67. King KF, Kolopack P, Merritt MW, Lavery JV. Community engagement and the human infrastructure of global health research. BMC Med Ethics. 2014; 15:84. doi: 10.1186/1472-6939-15-84 PMID: 25495054
68. The Wellcome Trust. Community engagement-under the microscope: international engagement workshop report. Wellcome Trust. Published June, 2011 [cited 2015 Jun 22]. Available from: http://www.wellcome.ac.uk/stellent/groups/corporatesite/@msh-grants/documents/web-document/wtvm054326.pdf.